The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.
STAT+: FDA approves Roivant therapy for rare autoimmune disease
Adam Feuerstein
The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.